As US drugmakers face growing resistance to the high price of cutting-edge treatments, a handful of companies are working on a new payment model that rewards them for the long-term performance of their medicines.
The effort, industry executives said, is being led by firms developing so-called gene therapies, which aim to cure inherited diseases like hemophilia by “fixing” the single faulty gene responsible for the disorder.
They include BioMarin Pharmaceutical Inc in San Rafael, California, and Sangamo BioSciences Inc in Richmond, California.
If these new hemophilia drugs and others like them succeed, a one-time infusion could replace the need for frequent, life-long injections of blood clotting proteins that can cost up to US$300,000 a year for a single patient. These existing treatments, including Pfizer Inc’s Xyntha and Baxter International’s Advate, are expected to command annual sales of more than US$11 billion by next year.
Drugmakers contend that a one-time cure, even at a price of more than US$1 million, would save money over the long term, but there are concerns that health insurers will balk at covering that kind of upfront cost.
“The place that we are moving toward is more of a pay-for-performance type of strategy,” Sangamo chief executive officer Edward Lanphier said. Under this model, the price would be amortized over a period of time and contingent on proof that the treatment is effective and safe.
The annuity-like payments would be stopped if medical testing, such as the level of clotting protein measured in a patient’s blood sample, showed that the therapy was not working.
Many barriers remain to implementing such a model, and the drugs for which it is being considered may not reach the market for several more years, if at all. Since Americans often switch health insurers, contracts — or even legislation — would be needed to require payers to pick up the ongoing tab for patients who change their coverage.
However, the interest in new payment models reflects the healthcare industry’s intention to find new ways to bolster profits as insurers push back against drug prices. Some backers of the new model say the payment streams could eventually be packaged and sold to investors, as happens now with securities backed by financial assets like credit card receivables.
“Our approach to this important funding-benefit question is to establish a financing vehicle where the relatively large upfront cost is amortized in conjunction with the benefit of these innovative, curative or preventative therapies,” said Michael Meyers, managing director and head of investment banking at T.R. Winston & Co, which is discussing such funding models with pharmaceutical and biotechnology companies.
Troyen Brennan, chief medical officer at CVS Health Corp, the second-largest US pharmacy benefit manager, is supportive of such efforts.
“Some sort of model where there was a partial payment over time could work well,” Brennan said in an interview.
Gene therapy has been a target of Big Pharma for more than 20 years, but research has been dogged by a series of disappointments and safety concerns. More recent scientific advances have paved the way for the potentially life-changing treatments.
No gene therapies have been approved in the US, but Europe approved its first gene therapy last year. Glybera treats a rare disorder that clogs the blood with fat and has been cleared for reimbursement in Germany at a price of 850,000 euros (US$963,000), or around US$1 million. It will be sold for a one-time payment because it is too difficult to measure how well it works, said Joern Aldag, CEO at Dutch biotech firm UniQure NV, which developed Glybera.
Aldag said gene therapies for larger patient populations in development at UniQure, including hemophilia and congestive heart failure, would likely be priced on an amortized basis.
“Gene therapy may be an initial very high burden for the healthcare system,” Aldag said. “The general consensus is that asking for a one-off payment of over a million dollars becomes unacceptable.”
However, insurers are much less willing to foot that kind of bill for drugs used in large numbers of patients. Last year, they pressured Gilead Sciences Inc to cut the US$1,000-per-pill cost of its new hepatitis C drug, saying the cost of treating more than 3 million Americans infected with the virus was unacceptable. Gilead said recently that it is discounting its prices by nearly 50 percent.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the